How Do We Manage Chronic Lymphocytic Leukemia in India

Area of Science:

• Hematology
• Oncology
• Public Health

Background:

• Chronic lymphocytic leukemia (CLL) was historically under-recognized in India due to low prevalence and limited treatment options.
• Healthcare in India presents a complex landscape with significant variations in population demographics, health systems, and reimbursement policies.

Purpose of the Study:

• To assess the current landscape and common issues in the management of CLL across India.
• To capture the perspectives of Indian hemato-oncologists on CLL diagnosis and treatment practices.

Main Methods:

• Incorporated opinions from three hemato-oncologists.
• Conducted an opinion poll involving 44 hemato-oncologists nationwide.
• Focused on common challenges and practices in CLL care pan-India.

Main Results:

• CLL diagnosis is increasingly occurring at earlier stages.
• Chemoimmunotherapy (CIT) retains a role due to limited insurance, but patient preference is shifting towards non-CIT options like Bruton's tyrosine kinase (BTK) inhibitors, driven by the availability of inexpensive generics.
• India's healthcare system is adapting with the availability of affordable generic targeted therapies and expanding insurance coverage.

Conclusions:

• The management of CLL in India is rapidly transforming, with a growing emphasis on prognostic markers and personalized treatment decisions.
• The increasing accessibility of generic targeted therapies and improved insurance coverage are making advanced treatments for CLL more attainable for Indian patients.
• India is well-positioned to meet the evolving needs of CLL patients, reflecting a significant shift in leukemia care within the country.